Novartis | NOVN - Operating Expenses


Novartis reported $9.29B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alcon AG USD 2.41B 4M Mar/2026
Almirall EUR 517.4M 32K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Autolus Therapeutics Ltd USD 85.73M 11.02M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Genmab DKK 798M 235M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
J&J USD 17.83B 388M Jun/2026
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.09B 687M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Orion EUR 345M 42.1M Jun/2026
Pfizer USD 90.1B 77.19B Mar/2026
Philips EUR 3.6B 775M Mar/2026
Recordati EUR 482.31M 98.3M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025